Speaker: 

Thomas Olenginski, MD, Staff Member, Geisinger - has nothing to disclose.

Moderator: 

Jay Bringman, MD, Staff Member, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Enumerate the 6 patient groups in the Geisinger Health System that are indicated to receive FDA approved therapy
• Explain the importance of treatment sequencing and treat to target
• Appraise possible adverse events related to our FDA approved agents

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Jay Bringman, MD; Sandra Culbertson, MD; Michelle Bafile, PA-C; Lindsay Payne; Stephanie Worhach and Dani Ashak, MD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant. 

Commercial Support for this Session

None